- Report
- January 2025
- 175 Pages
Global
From €4131EUR$4,490USD£3,459GBP
- Report
- May 2025
- 185 Pages
Global
From €3262EUR$3,545USD£2,731GBP
€3624EUR$3,939USD£3,034GBP
- Report
- August 2024
- 141 Pages
Global
From €2759EUR$2,999USD£2,310GBP
- Report
- May 2025
- 82 Pages
Global
From €5382EUR$5,850USD£4,506GBP
- Report
- April 2025
- 200 Pages
Global
From €4131EUR$4,490USD£3,459GBP
- Report
- November 2024
- 180 Pages
Global
From €4140EUR$4,500USD£3,466GBP
- Report
- February 2022
- 242 Pages
Global
From €2415EUR$2,625USD£2,022GBP
€4830EUR$5,250USD£4,044GBP
- Report
- April 2023
- 275 Pages
Global
From €3671EUR$3,990USD£3,073GBP
- Report
- August 2022
- 110 Pages
Global
From €4370EUR$4,750USD£3,659GBP
- Report
- July 2022
- 146 Pages
Global
From €4094EUR$4,450USD£3,428GBP
- Book
- December 2020
- 400 Pages
From €152EUR$165USD£127GBP
- Book
- February 2011
- 488 Pages
Hypercholesterolemia is a condition in which there is an abnormally high level of cholesterol in the blood. It is a major risk factor for cardiovascular disease, which is the leading cause of death worldwide. Cardiologists are responsible for diagnosing and treating hypercholesterolemia, as well as providing lifestyle advice to help reduce the risk of cardiovascular disease. Treatment options include lifestyle changes, such as diet and exercise, as well as medications, such as statins, which are used to reduce cholesterol levels.
The hypercholesterolemia market is a rapidly growing sector of the cardiology industry, with a focus on developing new treatments and therapies to reduce the risk of cardiovascular disease. Companies in this market include AstraZeneca, Merck, Pfizer, Sanofi, and Novartis. Show Less Read more
